李园珂

职称：副教授、博士生导师

教育背景：

2008-2012 中国药科大学   药物制剂  学士

2012-2015 中国药科大学   药剂学    硕士

2015-2020 美国密苏里大学 药剂学    博士

工作履历：

2020-2025 南开大学药物化学生物学全国重点实验室 助理研究员

2025-今   河北工业大学生命科学与健康工程学院 副教授、博士生导师

研究领域与承担项目：

研究领域：

1. 纳米医学与生物材料

肿瘤靶向递送、仿生纳米载体、核酸药物递送及功能化生物材料设计。

2. 肿瘤免疫与转化生物医药

肿瘤免疫微环境调控、免疫联合治疗、细胞膜工程及靶向多肽药物开发。

承担项目：

1. 国家自然基金青年科学项目C类，2022-2024，结题，主持

2. 河北省高等学校科学研究项目，产学研专项，2025-2027，在研，合作单位负责人

3. 国家自然基金面上项目，2024-2027，在研，参与

4. 南开大学-国药中生联合攻关项目子课题，2022-2023，结题，co-PI

National Cancer Institute, USA, R01, R01CA231099, Development of a targeted delivery platform for checkpoint inhibitors, 2018-06 至 2020-12, 结题, 参与

学术成果：

1.Yuanke Li, Haoqi Zhang, Ruikun Wang, Yuan Wang, Ruonan Li, Mingsheng Zhu, Xiangyun Zhang, Zhen Zhao, Yajuan Wan, Jie Zhuang, Hongkai Zhang*, Xinglu Huang*. Tumor Cell Nanovaccines Based on Genetically Engineered Antibody-Anchored Membrane. Advanced Materials. 2023, e2208923. (IF: 27.4)

2.Helong Kang^#, Yuanke Li^#, Fude Sun, Fan Li, Zheng Zhou, Jin Wu, Keyu Wang, Buayishamu Kutilike, Zhizhao Miao, Yanqin Xu, Dan Ding, Hongkai Zhang, Jie Zhuang*, Xinglu Huang* Modular Design of T Cell Nanoengagers for Tumor Immunotherapy via Genetically Engineered Lipid-Tagged Antibody Fragments. Advanced Materials. 2025, 2503060. (IF: 27.4)

3.Zhen Zhao^#; Yuanke Li^#; Hao Liu; Akshay Jain; Pratikkumar Vinodchandra Patel; Kun Cheng*; Co-delivery of IKBKE siRNA and Cabazitaxel by Hybrid Nanocomplex Inhibits Invasiveness and Growth of Triple-Negative Breast Cancer. Science Advances. 2020, 6(29): eabb0616. (IF: 14.95)

4.Haoqi Zhang^#, Yuanke Li^#, Helong Kang, Jingping Lan, Lin Hou, Zhengbang Chen, Fan Li, Yanqin Liu, Jiliang Zhao, Na Li, Yajuan Wan, Yiping Zhu, Zhen Zhao, Hongkai Zhang, Jie Zhuang*, Xinglu Huang*. Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer. Journal of Nanobiotechnology. 2024,22(1):104. (IF: 12.60)

5.Yuanke Li; Zhen Zhao^#; Chien-Yu Lin; Yanli Liu; Kevin F. Staveley-O Carroll; Guangfu Li; Kun Cheng*; Silencing PCBP2 Normalizes Desmoplastic Stroma and Improves the Antitumor Activity of Chemotherapy in Pancreatic Cancer. Theranostics. 2021, 11(5): 2182-2200 7. (IF: 11.6)

6.Yuanke Li, Zhen Zhao, Hao Liu, John Fetse, Akshay Jain, Chien-Yu Lin, Kun Cheng*. Development of a Tumor-Responsive Nanocomplex Targeting Pancreatic Cancer Cells and Stroma. ACS Applied Materials & Interfaces. 2019,11, p. 45390-45403. (IF: 8.19)

7.Yuanke Li, Yuanyuan Wu, Leaf Huang, Lei Miao, Jianping Zhou, Andrew Benson Satterlee, Jing Yao*. Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. Journal of Controlled Release. 2016, 228: 107-119. (IF: 10.33)

8.Yuanke Li^#, Ruiying Liu^#, Zhen Zhao*. Targeting Brain Drug Delivery with Macromolecules through Receptor-Mediated Transcytosis. Pharmaceutics. 2025.17 (IF: 4.9)

9.Yanqin Liu, Qiongqiong Ma, Kailu Yang, Dongping Zhang, Fan Li, Jingru Chen, Feilong Zhou, Han Wang, Na Li, Yuan Wang, Youjia Cao, Cuizhu Zhang, Xin Li, Hongkai Zhang, Wei Wang, Yuanke Li*. Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy. Biochemical and Biophysical Research Communications. 2024, 698:19546. (IF: 2.55)

10.Fan Li^#, Jingru Chen^#, Yuanke Li^#, Wei Wang, Yi Yang, Jie Wang, Minghui Han, Han Wang, Feilong Zhou, Wenxuan Ma, Yi Wang, Zhaoyuan Zhang, Jufeng Yu, Zhen Zhao, Li Deng, Shiyu Liu, Yajuan Wan, Zhigang Zhao, Song Xu, Jiangmei Li, Youjia Cao, Hongkai Zhang* Oncolytic virus-induced IL-1β monocyte-IL-6+ CAF axis suppresses dendritic cell-mediated antitumor immunity in pancreatic cancer. Journal for Immunotherapy of Cancer. 2025 Nov 18;13(11):e013175. (IF: 10.6)